



# **Long Covid Update - a threat that continues to demand a strong response**

6 March 2025

John D Potter, Michael Baker, Amanda Kvalsvig

# Summary

Long Covid (LC) remains a risk following any Covid-19 infection or reinfection. It includes a syndrome of long-term symptoms, a substantially increased risk of sudden death, and silent cell and organ damage that may predispose to later illness. Consequently, it produces a large burden of illness for our communities, healthcare system, and economy. Covid-19 vaccination reduces the risk of LC following Omicron infection, but there is still around a 10% risk of LC among vaccinated individuals.

Aotearoa New Zealand (NZ) needs a coordinated response from Government to minimise LC incidence and impact. In addition to funding treatment and support services, this strategy must include public health and social measures to protect individuals and populations from exposure to Covid-19. We also need a programme to maximise vaccine coverage across all age groups, including young people and pregnant women. These interventions must be supported by a concerted and clear information campaign, targeted surveillance, and research.

---

Five years of experience with Covid-19 has provided substantial evolving evidence on Long Covid (LC), which we review here to assess risk and the necessary proportionate prevention-and-management response. Aotearoa New Zealand (NZ) has had three years of intense exposure to this infection.<sup>1</sup> The [pandemic persists](#), albeit in more muted fashion, with recurring waves and persistently high baseline levels of infection year-round, raising concerns about the impact of recurrent infection.<sup>2</sup>

Updating a [Briefing from almost a year ago](#),<sup>3</sup> we focus on recent evidence. An [Appendix](#) (available as a downloadable PDF) provides additional background information.

## Impact of Long Covid

LC is defined by the UK National Institute for Health and Care Excellence, as: “Signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis. It usually presents with clusters of symptoms, often overlapping, which can fluctuate and change over time and can affect any system in the body...”.<sup>4</sup> LC is also seen as “the constellation of post-acute and long-term health effects caused by SARS-CoV-2 infection”.<sup>5</sup>

These definitions fall short of considering the whole spectrum of SARS-CoV-2 consequences. Indeed, later health consequences of acute infection include both symptomatic Covid and asymptomatic changes at cellular and organ-system level that predispose to a range of delayed outcomes and involve multiple pathophysiologic processes (see [Appendix](#)). These delayed outcomes include sudden death,<sup>6-10</sup> as well as ‘silent’ cell and organ damage that may predispose to later illness, particularly among children and young people,<sup>11-13</sup> (see [Appendix](#)). Here, we consider all these downstream consequences as aspects of LC.

Essentially every organ system can be involved in clinical LC, including cardiovascular,<sup>14-16</sup> musculo-skeletal,<sup>17</sup> nervous,<sup>18-24</sup> immune,<sup>25-29</sup> gastrointestinal,<sup>30-33</sup> endocrine,<sup>34-38</sup> renal,<sup>39</sup> and reproductive systems.<sup>40</sup> It impacts individuals of all ages, all ethnicities, both sexes and all genders, but is more common in biological females. LC reduces quality of life, and can cause loss of ability to work and, sometimes, severe disability. Signature manifestations

include: cognitive dysfunction (“brain fog”),<sup>41-43</sup> reported in Aotearoa even among young people (see [Appendix](#)),<sup>43</sup> fatigue,<sup>44-45</sup> post-exertional malaise,<sup>17-46</sup> and postural orthostatic tachycardia syndrome as a consequence of autonomic nervous system dysfunction.<sup>46-48</sup> Long-term consequences include myocardial infarction,<sup>14-16-49</sup> stroke,<sup>14-16</sup> and new-onset diabetes.<sup>34-37-38-50</sup> LC is part of a family of infection-associated chronic conditions.<sup>45-46-51-59</sup>

## Risk of LC

Estimates of the initial incidence of LC after acute infection are 50–85% among those both unvaccinated and hospitalised, 10–35% among the unvaccinated but not hospitalised, and 8–12% among those vaccinated.<sup>60</sup> A meta-analysis of 194 studies with 735,006 participants reports that ≥45% of Covid-19 survivors, regardless of hospitalisation status, experience at least one unresolved symptom at 126 days.<sup>61</sup> The cumulative global incidence of LC is estimated across a range of 65 million<sup>62</sup> to 400 million.<sup>5</sup> (see also the [Appendix](#) for a discussion of the marked variability of risk estimates).

The Omicron variant has been associated with a lower per-infection risk of LC than Delta and pre-Delta variants.<sup>63</sup> In both children and adults, vaccination<sup>23-38-63-76</sup> and, in adults, antivirals as treatment for acute Covid,<sup>77-78</sup> reduce risk of LC. Reinfection is a risk factor<sup>64-79</sup> and each infection carries risk irrespective of whether an earlier infection was followed by LC,<sup>64-79-80</sup> including in children and young people.<sup>81</sup> Each reinfection can result in new LC or exacerbate the severity of existing symptoms.<sup>64-79</sup> Cumulatively, two infections are associated with a greater risk of LC than one, and three increase risk more than two.<sup>64-79</sup>

One positive development in NZ is that the incidence of Covid-19 [decreased in 2024](#) compared with the previous two years, partly driven by the [lack of an expected wave](#) over the 2024-25 summer. It is too soon to know if this pattern will continue. However, risk of LC remains high and [results in a large burden of illness for our communities, healthcare system, and economy](#).<sup>82</sup>

## Responding to LC

The best protection against LC is avoiding infection using proven public health and social measures to reduce exposure to the virus, notably: testing and case isolation; improved indoor ventilation; and masking in high-risk indoor environments. Other measures are vaccination to reduce the risk of infection and LC, and antiviral treatment to reduce progression to LC. A coordinated, evidence-informed governmental response is essential. This strategy needs to include coverage of key indoor environments such as schools,<sup>83</sup> healthcare facilities, and public transport.<sup>84</sup>

The NZ Government response to LC has been markedly inadequate. A Long COVID Expert Advisory Group was established in May 2022 to assess the evidence on LC and provide recommendations for clinical practice.<sup>85</sup> It lacked specialists in key areas, including infectious disease, neurology, cardiology, and immunology. Their (revised) guidelines were published in December 2022<sup>86</sup> and work concluded in November 2022; they have not been reactivated or replaced.

The Report of the Royal Commission of Inquiry into Covid-19,<sup>87</sup> like our previous report on LC,<sup>3</sup> disappeared like a rock in a lake of indifference.<sup>88</sup> Health organisations attempting to provide LC services to staff and communities are hampered by lack of funding.<sup>89-90</sup> If only 5% of the population of Aotearoa (a low-end estimate) have LC, that involves >250,000

people; our only LC registry includes about 1200.<sup>91 92</sup> A NZ [extrapolation of Australian data](#) suggests that LC will result in a GDP loss around NZ\$2 billion per year.<sup>82</sup> (also see [Appendix](#))

## What this Briefing adds

- LC remains a risk following any Covid-19 infection or reinfection. This risk includes an increased probability of sudden death and 'silent' cell and organ damage
- Covid-19 vaccination reduces the risk of LC following Omicron infection but there is still around a 10% risk of LC among vaccinated individuals
- Consequently, LC results in a large burden of illness for our communities, healthcare system and economy
- There is growing international evidence of the economic burden of LC: Australian data suggest a GDP loss for NZ of around NZ\$2 billion per year

## Implications for policy and practice

- Develop a coordinated NZ Government response to LC with input from a suitably broad-based advisory group
- Implement a prevention strategy to protect individuals and populations from Covid-19 infection, including key settings such as schools, healthcare, workplaces, and public transport
- Promote continuing high Covid-19 vaccine coverage across all age groups, including young people and pregnant women (which provides added protection of the newborn)
- Implement effective surveillance for LC and research to investigate important NZ questions
- Require Te Whata Ora/Health New Zealand to develop and regularly evaluate accessible specialist LC services and treatment pathways

## Authors details

[Prof John D Potter](#) Centre for Public Health Research, Massey University | Te Kunenga ki Pūrehuroa

[Prof Michael Baker](#), University of Otago Wellington | Te Whare Wānanga o Otāgo ki Te Whanga-nui-a-Tara

[Assoc Prof Amanda Kvalsvig](#), University of Otago Wellington | Te Whare Wānanga o Otāgo ki Te Whanga-nui-a-Tara

## Appendix

An appendix for this article is available as a separate PDF.

[Appendix - Long Covid Update – a threat that continues to demand a strong response \(PDF\)](#)

## References

1. Baker MG, Kvalsvig A, Plank MJ, et al. Continued mitigation needed to minimise the high health burden from COVID-19 in Aotearoa New Zealand. *N Z Med J* 2023;136(1583):67-91. doi: 10.26635/6965.6247 [published Online First: 20231006]
2. Baker M, Kvalsvig A, Potter JD, et al. Five years on, Covid-19 remains NZ's most important infectious disease - it still demands a strong response. *Public Health Expert Briefing* (26 February 2025). <https://www.phcc.org.nz/briefing/five-years-covid-19-remains-nzs-most-important-infectious-disease-it-still-demands-strong> (accessed 26 February 2025).
3. Kvalsvig A, Brooks AES, Potter JD, et al. Long Covid in Aotearoa NZ: Risk assessment and preventive action urgently needed. *Public Health Expert Briefing* (26 Mar 2024). <https://www.phcc.org.nz/briefing/long-covid-aotearoa-nz-risk-assessment-and-preventive-action-urgently-needed> (accessed 26 Mar 2024).
4. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. <https://www.nice.org.uk/guidance/ng188>: National Institute for Health and Care Excellence, 2024.
5. Al-Aly Z, Davis H, McCorkell L, et al. Long COVID science, research and policy. *Nat Med* 2024;30(8):2148-64. doi: 10.1038/s41591-024-03173-6 [published Online First: 20240809]
6. Scholey J, Aburto JM, Kashnitsky I, et al. Life expectancy changes since COVID-19. *Nat Hum Behav* 2022;6(12):1649-59. doi: 10.1038/s41562-022-01450-3 [published Online First: 20221017]
7. Stokes AC, Lundberg DJ, Elo IT, et al. COVID-19 and excess mortality in the United States: A county-level analysis. *PLoS Med* 2021;18(5):e1003571. doi: 10.1371/journal.pmed.1003571 [published Online First: 20210520]
8. Iwashyna TJ, Seelye S, Berkowitz TS, et al. Late Mortality After COVID-19 Infection Among US Veterans vs Risk-Matched Comparators: A 2-Year Cohort Analysis. *JAMA Intern Med* 2023;183(10):1111-19. doi: 10.1001/jamainternmed.2023.3587 [published Online First: 20230821]
9. Bilinski A, Emanuel EJ. COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries. *JAMA* 2020;324(20):2100-02. doi: 10.1001/jama.2020.20717 [published Online First: 2020/10/13]
10. Han L, Zhao S, Li S, et al. Excess cardiovascular mortality across multiple COVID-19 waves in the United States from March 2020 to March 2022. *Nat Cardiovasc Res* 2023;2(3):322-33. doi: 10.1038/s44161-023-00220-2 [published Online First: 20230227]
11. Østergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. *Physiol Rep* 2021;9(3):e14726. doi: 10.14814/phy2.14726
12. Wu X, Xiang M, Jing H, et al. Damage to endothelial barriers and its contribution to long COVID. *Angiogenesis* 2024;27(1):5-22. doi: 10.1007/s10456-023-09878-5 [published Online First: 20230427]
13. Yonts AB. Pediatric Long-COVID: A Review of the Definition, Epidemiology, Presentation, and Pathophysiology. *Pediatr Ann* 2022;51(11):e416-e20. doi: 10.3928/19382359-20220913-06 [published Online First: 20221101]
14. Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. *Nat Med* 2022;28(3):583-90. doi: 10.1038/s41591-022-01689-3 [published Online First: 2022/02/09]
15. Wan EYF, Mathur S, Zhang R, et al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank.

*Cardiovasc Res* 2023;119(8):1718-27. doi: 10.1093/cvr/cvac195

16. Battistoni A, Volpe M, Morisco C, et al. Persistent increase of cardiovascular and cerebrovascular events in COVID-19 patients: a 3-year population-based analysis. *Cardiovasc Res* 2024;120(6):623-29. doi: 10.1093/cvr/cvae049
17. Appelman B, Charlton BT, Goulding RP, et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. *Nature Communications* 2024;15(1):17. doi: 10.1038/s41467-023-44432-3 [published Online First: 20240104]
18. Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. *Bmj* 2022;376:e068993. doi: 10.1136/bmj-2021-068993 [published Online First: 20220216]
19. Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. *Nat Med* 2022;28(11):2406-15. doi: 10.1038/s41591-022-02001-z [published Online First: 20220922]
20. Atchison CJ, Davies B, Cooper E, et al. Long-term health impacts of COVID-19 among 242,712 adults in England. *Nat Commun* 2023;14(1):6588. doi: 10.1038/s41467-023-41879-2 [published Online First: 20231024]
21. Greene C, Connolly R, Brennan D, et al. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. *Nat Neurosci* 2024;27(3):421-32. doi: 10.1038/s41593-024-01576-9 [published Online First: 20240222]
22. Seighali N, Abdollahi A, Shafiee A, et al. The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis. *BMC Psychiatry* 2024;24(1):105. doi: 10.1186/s12888-023-05481-6 [published Online First: 20240206]
23. Walker VM, Patalay P, Cuitun Coronado JI, et al. COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People. *JAMA Psychiatry* 2024;81(11):1071-80. doi: 10.1001/jamapsychiatry.2024.2339
24. Zhao S, Martin EM, Reuken PA, et al. Long COVID is associated with severe cognitive slowing: a multicentre cross-sectional study. *EClinicalMedicine* 2024;68:102434. doi: 10.1016/j.eclinm.2024.102434 [published Online First: 20240125]
25. Altmann DM, Whettlock EM, Liu S, et al. The immunology of long COVID. *Nature reviews Immunology* 2023;23(10):618-34. doi: 10.1038/s41577-023-00904-7 [published Online First: 2023/07/12]
26. Ewing A. COVID-19 and Immune Dysregulation, a Summary and Resource. *WHN Science Communications* 2023 5 March, 2023. <https://whn.global/scientific/covid19-immune-dysregulation/> (accessed 27 Dec 2023).
27. Klein J, Wood J, Jaycox JR, et al. Distinguishing features of long COVID identified through immune profiling. *Nature* 2023;623(7985):139-48. doi: 10.1038/s41586-023-06651-y [published Online First: 20230925]
28. Cervia-Hasler C, Bruning SC, Hoch T, et al. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. *Science* 2024;383(6680):eadg7942. doi: 10.1126/science.adg7942 [published Online First: 20240119]
29. Peluso MJ, Ryder D, Flavell RR, et al. Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection. *Sci Transl Med* 2024;16(754):eadk3295. doi: 10.1126/scitranslmed.adk3295 [published Online First: 20240703]
30. Xu E, Xie Y, Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. *Nat Commun* 2023;14(1):983. doi: 10.1038/s41467-023-36223-7 [published Online First: 20230307]
31. Su Q, Lau RI, Liu Q, et al. Post-acute COVID-19 syndrome and gut dysbiosis linger

- beyond 1 year after SARS-CoV-2 clearance. *Gut* 2023;72(6):1230-32. doi: 10.1136/gutjnl-2022-328319 [published Online First: 20220808]
32. Elmunzer BJ, Palsson OS, Forbes N, et al. Prolonged Gastrointestinal Manifestations After Recovery From COVID-19. *Clin Gastroenterol Hepatol* 2024;22(5):1098-107 e3. doi: 10.1016/j.cgh.2023.11.009 [published Online First: 20231122]
  33. Golla R, Vuyyuru S, Kante B, et al. Long-term Gastrointestinal Sequelae Following COVID-19: A Prospective Follow-up Cohort Study. *Clin Gastroenterol Hepatol* 2023;21(3):789-96 e1. doi: 10.1016/j.cgh.2022.10.015 [published Online First: 20221021]
  34. Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. *Diabetologia* 2022;65(6):949-54. doi: 10.1007/s00125-022-05670-0 [published Online First: 20220316]
  35. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. *Lancet Diabetes Endocrinol* 2022;10(5):311-21. doi: 10.1016/S2213-8587(22)00044-4 [published Online First: 20220321]
  36. Kendall EK, Olaker VR, Kaelber DC, et al. Association of SARS-CoV-2 Infection With New-Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021. *JAMA Netw Open* 2022;5(9):e2233014. doi: 10.1001/jamanetworkopen.2022.33014 [published Online First: 20220901]
  37. Weiss A, Donnachie E, Beyerlein A, et al. Type 1 Diabetes Incidence and Risk in Children With a Diagnosis of COVID-19. *Jama* 2023;329(23):2089-91. doi: 10.1001/jama.2023.8674 [published Online First: 20230522]
  38. Taylor K, Eastwood S, Walker V, et al. Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people. *Lancet Diabetes Endocrinol* 2024;12(8):558-68. doi: 10.1016/S2213-8587(24)00159-1
  39. Bowe B, Xie Y, Xu E, et al. Kidney Outcomes in Long COVID. *J Am Soc Nephrol* 2021;32(11):2851-62. doi: 10.1681/ASN.2021060734 [published Online First: 2021/09/03]
  40. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat Med* 2022;28(8):1706-14. doi: 10.1038/s41591-022-01909-w [published Online First: 20220725]
  41. Hampshire A, Azor A, Atchison C, et al. Cognition and Memory after Covid-19 in a Large Community Sample. *N Engl J Med* 2024;390(9):806-18. doi: 10.1056/NEJMoa2311330
  42. Leng A, Shah M, Ahmad SA, et al. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. *Cells* 2023; 12(5).
  43. McNeill R, Marshall R, Fernando SA, et al. COVID-19 may Enduringly Impact cognitive performance and brain haemodynamics in undergraduate students. *Brain Behav Immun* 2024;125:58-67. doi: 10.1016/j.bbi.2024.12.002 [published Online First: 20241219]
  44. Gottlieb M, Wang RC, Yu H, et al. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. *Clin Infect Dis* 2023;76(11):1930-41. doi: 10.1093/cid/ciad045
  45. Unger ER, Lin JS, Wisk LE, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection. *JAMA Netw Open* 2024;7(7):e2423555. doi: 10.1001/jamanetworkopen.2024.23555 [published Online First: 20240701]
  46. National Academies of Sciences Engineering and Medicine. Long-Term Health Effects of COVID-19: Disability and Function Following SARS-CoV-2 Infection. Washington, DC: The National Academies Press, 2024.

47. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. *Immunol Res* 2021;69(2):205-11. doi: 10.1007/s12026-021-09185-5 [published Online First: 20210330]
48. Seeley MC, Gallagher C, Ong E, et al. High Incidence of Autonomic Dysfunction and Postural Orthostatic Tachycardia Syndrome in Patients with Long COVID: Implications for Management and Health Care Planning. *Am J Med* 2023;138(2):354-61 e1. doi: 10.1016/j.amjmed.2023.06.010 [published Online First: 20230629]
49. Lala A, Johnson KW, Januzzi JL, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. *J Am Coll Cardiol* 2020;76(5):533-46. doi: 10.1016/j.jacc.2020.06.007 [published Online First: 2020/06/11]
50. D'Souza D, Empringham J, Pechlivanoglou P, et al. Incidence of Diabetes in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis. *JAMA Netw Open* 2023;6(6):e2321281. doi: 10.1001/jamanetworkopen.2023.21281 [published Online First: 20230601]
51. Choutka J, Jansari V, Hornig M, et al. Unexplained post-acute infection syndromes. *Nature medicine* 2022;28(5):911-23. doi: 10.1038/s41591-022-01810-6 [published Online First: 20220518]
52. Walitt B, Singh K, LaMunion SR, et al. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. *Nat Commun* 2024;15(1):907. doi: 10.1038/s41467-024-45107-3 [published Online First: 20240221]
53. Jason LA, Natelson BH, Bonilla H, et al. What Long COVID investigators can learn from four decades of ME/CFS research. *Brain Behavior and Immunity Integrative* 2023;4:100022. doi: 10.1016/j.bbii.2023.100022
54. Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. *Front Med (Lausanne)* 2023;10:1187163. doi: 10.3389/fmed.2023.1187163 [published Online First: 20230602]
55. Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. *Bmj* 2006;333(7568):575. doi: 10.1136/bmj.38933.585764.AE [published Online First: 20060901]
56. Annesley SJ, Missailidis D, Heng B, et al. Unravelling shared mechanisms: insights from recent ME/CFS research to illuminate long COVID pathologies. *Trends in molecular medicine* 2024;30(5):443-58. doi: 10.1016/j.molmed.2024.02.003 [published Online First: 20240304]
57. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. *J Rehabil Med* 2020;52(5):jrm00063. doi: 10.2340/16501977-2694 [published Online First: 20200531]
58. Marshall-Gradisnik S, Eaton-Fitch N. Understanding myalgic encephalomyelitis. *Science* 2022;377(6611):1150-51. doi: 10.1126/science.abo1261 [published Online First: 20220908]
59. Trojan DA, Cashman NR. Post-poliomyelitis syndrome. *Muscle Nerve* 2005;31(1):6-19. doi: 10.1002/mus.20259
60. Greenhalgh T, Sivan M, Perlowski A, et al. Long COVID: a clinical update. *Lancet* 2024;404(10453):707-24. doi: 10.1016/S0140-6736(24)01136-X [published Online First: 20240731]
61. O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic



- review and meta-analysis. *EClinicalMedicine* 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762 [published Online First: 20221201]
62. Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023;21(3):133-46. doi: 10.1038/s41579-022-00846-2 [published Online First: 20230113]
63. Xie Y, Choi T, Al-Aly Z. Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras. *N Engl J Med* 2024;391(6):515-25. doi: 10.1056/NEJMoa2403211 [published Online First: 20240717]
64. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. *Nat Med* 2022;28(11):2398-405. doi: 10.1038/s41591-022-02051-3 [published Online First: 2022/11/11]
65. Brannock MD, Chew RF, Preiss AJ, et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. *Nat Commun* 2023;14(1):2914. doi: 10.1038/s41467-023-38388-7 [published Online First: 20230522]
66. Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. *Nat Med* 2023;29(9):2347-57. doi: 10.1038/s41591-023-02521-2 [published Online First: 20230821]
67. Lundberg-Morris L, Leach S, Xu Y, et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. *Bmj* 2023;383:e076990. doi: 10.1136/bmj-2023-076990 [published Online First: 20231122]
68. Yousaf AR, Mak J, Gwynn L, et al. 1935. COVID-19 mRNA Vaccination Reduces the Occurrence of Post-COVID Conditions in U.S. Children Aged 5-17 Years Following Omicron SARS-CoV-2 Infection, July 2021-September 2022. *Open Forum Infectious Diseases* 2023;10(Supplement\_2):ofad500.2466. doi: 10.1093/ofid/ofad500.2466
69. Ceban F, Kulzhabayeva D, Rodrigues NB, et al. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. *Brain Behav Immun* 2023;111:211-29. doi: 10.1016/j.bbi.2023.03.022 [published Online First: 20230327]
70. Byambasuren O, Stehlik P, Clark J, et al. Effect of covid-19 vaccination on long covid: systematic review. *BMJ Med* 2023;2(1):e000385. doi: 10.1136/bmjmed-2022-000385 [published Online First: 20230201]
71. Razzaghi H, Forrest CB, Hirabayashi K, et al. Vaccine Effectiveness Against Long COVID in Children. *Pediatrics* 2024;153(4):e2023064446. doi: 10.1542/peds.2023-064446
72. Mercade-Besora N, Li X, Kolde R, et al. The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. *Heart* 2024;110(9):635-43. doi: 10.1136/heartjnl-2023-323483 [published Online First: 20240415]
73. Ballouz T, Menges D, Kaufmann M, et al. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. *PLoS One* 2023;18(2):e0281429. doi: 10.1371/journal.pone.0281429 [published Online First: 20230222]
74. Wan EYF, Mok AHY, Yan VKC, et al. Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study. *Cell Rep Med* 2023;4(10):101195. doi: 10.1016/j.xcrm.2023.101195 [published Online First: 20230915]
75. Trinh NT, Jodicke AM, Catala M, et al. Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway. *Lancet Respir Med* 2024;12(5):e33-e34. doi: 10.1016/S2213-2600(24)00082-1 [published Online First: 20240410]

76. Catala M, Mercade-Besora N, Kolde R, et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. *Lancet Respir Med* 2024;12(3):225-36. doi: 10.1016/S2213-2600(23)00414-9 [published Online First: 20240111]
77. Sun G, Lin K, Ai J, et al. The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis. *Clin Microbiol Infect* 2024;30(12):1505-13. doi: 10.1016/j.cmi.2024.07.006 [published Online First: 20240714]
78. Wang H, Wei Y, Hung CT, et al. Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study. *Lancet Infect Dis* 2024;24(10):1130-40. doi: 10.1016/S1473-3099(24)00217-2 [published Online First: 20240503]
79. Kuang S, Earl S, Clarke J, et al. Experiences of Canadians with long-term symptoms following COVID-19. 2023 December 8, 2023. [https://www150.statcan.gc.ca/n1/en/pub/75-006-x/2023001/article/00015-eng.pdf?st=ljmM-B\\_J](https://www150.statcan.gc.ca/n1/en/pub/75-006-x/2023001/article/00015-eng.pdf?st=ljmM-B_J) (accessed 17 Dec 2023).
80. Bosworth ML, Shenhuy B, Walker AS, et al. Risk of New-Onset Long COVID Following Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2: A Community-Based Cohort Study. *Open Forum Infectious Diseases* 2023;10(11):ofad493. doi: 10.1093/ofid/ofad493 [published Online First: 20231005]
81. Stephenson T, Pinto Pereira SM, Nugawela MD, et al. A 24-month National Cohort Study examining long-term effects of COVID-19 in children and young people. *Commun Med (Lond)* 2024;4(1):255. doi: 10.1038/s43856-024-00657-x [published Online First: 20241204]
82. Kvalsvig A, Kerr J, Lorgelly P, et al. Long Covid: High economic burden justifies further preventive efforts. *Public Health Expert Briefing* (9 Sept 2024). <https://www.phcc.org.nz/briefing/long-covid-high-economic-burden-justifies-further-preventive-efforts> (accessed 9 Sept 2024).
83. Kvalsvig A, Tuari-Toma B, Timu-Parata C, et al. Protecting school communities from COVID-19 and other infectious disease outbreaks: the urgent need for healthy schools in Aotearoa New Zealand. *NZ Med J* 2023;136(1571):7-19. doi: 10.26635/6965.e1571 [published Online First: 20230310]
84. Wilson N, Barnard LT, Bennett J, et al. Poor ventilation in public transport settings in Aotearoa NZ: New data for buses and trains. *PHCC Briefing* 2023 10 July 2023. <https://www.phcc.org.nz/briefing/poor-ventilation-public-transport-settings-aotearoa-nz-new-data-buses-and-trains> (accessed 28 Jan 2025).
85. Health New Zealand Te Whatu Ora. Long COVID Expert Advisory Group. 2024 Last updated: 2 April 2024. (accessed 16 Dec 2024).
86. Ministry of Health. Clinical Rehabilitation Guideline for People with Long COVID (Coronavirus Disease) in Aotearoa New Zealand. [https://www.health.govt.nz/system/files/2022-09/clinical\\_rehabilitation\\_guideline\\_for\\_people\\_with\\_long\\_covid\\_13\\_dec.pdf](https://www.health.govt.nz/system/files/2022-09/clinical_rehabilitation_guideline_for_people_with_long_covid_13_dec.pdf): Ministry of Health, 2022.
87. New Zealand Royal Commission COVID-19 Lessons Learned. Looking back to move forward: Aotearoa New Zealand's Experiences of the COVID-19 pandemic. <https://www.covid19lessons.royalcommission.nz/assets/Report-pdfs/experiences.pdf>: New Zealand Royal Commission COVID-19 Lessons Learned, 2024.
88. Baker M, Kvalsvig A, Tukuitonga C, et al. The Covid inquiry report is an excellent guide to preparing for the next pandemic – health cuts put that at risk. *PHCC Briefing* 2024 5 December 2024. <https://www.phcc.org.nz/briefing/covid-inquiry-report-excellent-guide-preparing-next-pandemic-health-cuts-put-risk> (accessed 28 Jan 2025).

89. Huston, Jemima. Taranaki healthcare staff volunteer to help colleagues with Long Covid. *RNZ* 2023 19 October 2023. <https://www.rnz.co.nz/news/national/500537/taranaki-healthcare-staff-volunteer-to-help-colleagues-with-long-covid> (accessed 16 Dec 2024).
90. Zaidi S, Dunford F, Jarman J. Long COVID Staff Clinic: Caring for carers in Taranaki. *Public Health Expert Briefing* (11 May 2023). <https://www.phcc.org.nz/briefing/long-covid-staff-clinic-caring-carers-taranaki> (accessed 16 Dec 2024).
91. Russell L, Jeffreys M, Cumming J, et al. Impacts of Covid-19 in Aotearoa (Ngā Kawekawe o Mate Korona). <https://covid.aotearoa.com/wp-content/uploads/2023/01/Nga-Kawekawe-o-Mate-Korona-Full-Report-2023-01-24.pdf>: Victoria University of Wellington., 2022.
92. Lorgelly PK, Crossan J, Exeter DJ, et al. The Burden of Long COVID in Aotearoa New Zealand: Establishing a Registry. Final Report to the Ministry of Health. [https://lcregistry.auckland.ac.nz/files/2024/06/report\\_to\\_MoH.pdf](https://lcregistry.auckland.ac.nz/files/2024/06/report_to_MoH.pdf): University of Auckland & Long Covid Support Aotearoa, 2024.



Public Health Expert Briefing (ISSN 2816-1203)

---

**Source URL:**

<https://www.phcc.org.nz/briefing/long-covid-update-threat-continues-demand-strong-response>